Page 2 - Daniel Alkon News Today

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders,...

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative...

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative...

Synaptogenix Announces Phase 2b NIH Sponsored Alzheimers Disease Trial Update - Data Safety Monitoring Board confirms Bryostatin-1 Safety News provided by Share this article Share this article NEW YORK, June 9, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on its ongoing National Institutes of Health ("NIH") sponsored Phase 2b clinical trial of Bryostatin-1...

Press release content from PR Newswire. The AP news staff was not involved in its creation. Synaptogenix to Present at Sachs 4th Annual Neuroscience Innovation Forum April 26, 2021 GMT NEW YORK, April 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) (“Synaptogenix” or the “Company”), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Dr. Daniel Alkon, the Company’s President and Chief Scientific Officer, wi...

Synaptogenix to Present at Upcoming Scientific Industry Conferences News provided by Share this article Share this article NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will attend two upcoming scientific industry conferences.   On Thursday, February 25 th, Dr. Daniel Alkon M.D., President and Chief Scientific Officer, will present a virtual...

New Study Demonstrates Bryostatin Normalizes Autistic Spectrum Behaviors in Mice - Peer Reviewed Article Published through Nature.com News provided by Share this article Share this article NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), formerly Neurotrope Bioscience, Inc., announced a new report published by "Scientific Reports," an open-access journal publishing peer reviewed research through Nature.com, titled "Chronic Bryostatin-1 rescues autistic and cognitive phe...